A Double-Blind, Randomized, Multicenter, Parallel Group Study to Evaluate the Effects of Aliskiren, Ramipril and Combination Treatment on Plasma Concentration of Angiotensin II in Patients With Decompensated Chronic Systolic Heart Failure.
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2014
At a glance
- Drugs Aliskiren (Primary) ; Ramipril (Primary)
- Indications Decompensated heart failure
- Focus Biomarker; Pharmacodynamics
- Acronyms ESCAPE-SHF
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 23 May 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2008-001035-35).
- 02 Mar 2012 Actual patient number (123) added as reported by ClinicalTrials.gov.